PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)

PURPOSE: Triple-negative breast cancer (TNBC) has a poor outcome compared to other subtypes, even in those with early disease. Immune checkpoint inhibitors (ICIs) have been approved in metastatic diseases and are being tested as a neoadjuvant strategy also. The response to ICIs is largely determined...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ecancermedicalscience
Glavni autori: Ghosh, Joydeep, Chatterjee, Meheli, Ganguly, Sandip, Datta, Anupurva, Biswas, Bivas, Mukherjee, Geetashree, Agarwal, Sanjit, Ahmed, Rosina, Chatterjee, Sanjoy, Dabkara, Deepak
Format: Artigo
Jezik:Inglês
Izdano: Cancer Intelligence 2021
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183644/
https://ncbi.nlm.nih.gov/pubmed/34158821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1217
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items